PsyMed Ventures
PsyMed Ventures is a San Francisco-based venture capital fund investing exclusively in early-stage companies developing frontier brain and mental health technologies. The firm manages a 20+ company portfolio spanning neurotech, psychedelic therapeutics, RNA medicines, neurostimulation, digital health, and AI-assisted therapy, sourcing deals via founder networks and its Business Trip podcast.
- Company typePrivate
- Founded2020
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What PsyMed Ventures does
PsyMed Ventures is a San Francisco-based venture capital fund founded circa 2022 that invests exclusively in early-stage companies developing frontier brain and mental health technologies. The firm defines its thesis across eight focus areas: artificial intelligence, neurotech and human augmentation (including brain-computer interfaces), precision neuroscience, new modalities (genetic, RNA, cell therapies), holistic medicine, neurometabolism, platforms and novel therapeutics, and digital health/therapeutics. Its 20+ company active portfolio spans modalities including RNAi medicines for neurodegeneration (Aerska, Iris Medicine, Sculpta Bio), CRISPR for live biotherapeutics (Ancilia), psychedelic therapeutics (Bright Minds, Delix Therapeutics, Mindstate Design Labs, Freedom Biosciences), ketamine formulations (Bexson Biomedical), microbiome therapeutics (Bloom Science), bioelectronics for treatment-resistant depression (Motif Neurotech), transcranial focused ultrasound (Sanmai), VR/AR meditation (TRIPP), and AI-assisted therapy (Jimini Health).
The fund is led by co-founders Matias Serebrinsky (General Partner, previously NVIDIA Inception North America lead and CookUnity co-founder) and Dina Burkitbayeva (CEO of Freedom Biosciences), alongside partner Greg Kubin. The investment team is supplemented by a deep bench of venture partners and scientific advisors with neuroscience, clinical, and biotech credentials, including Tim Gardner PhD (former Neuralink founding member), John Krystal MD (Chief of Psychiatry at Yale-New Haven Hospital), Jacob Robinson PhD (Rice University, Motif Neurotech CEO), and Negin Mohktari PhD (previously Partner at Bioluminescence Ventures). PsyMed does not develop proprietary technology but rather allocates capital and provides strategic support—regulatory guidance, scientific mentorship, and ecosystem connections—to specialized founders.
The firm generates returns through standard venture capital mechanics: management fees on committed capital and carried interest on fund profits, realized through portfolio company IPOs, acquisitions, and secondary transactions. Realized exits include IPOs of Bright Minds and Delix Therapeutics, and acquisitions of Gilgamesh Pharmaceuticals, Humans Anonymous, and Imyoo. Deal sourcing is conducted through founder networks, the Business Trip podcast (co-hosted by the two GPs), a Substack newsletter, social media, and industry events. The customer base is dual-sided: founders building brain and mental health companies (primary, receiving capital and support) and limited partners (secondary, receiving exposure to a curated, sector-specialized portfolio).
PsyMed Ventures firmographics
Firmographics- Name
- PsyMed Ventures
- Legal name
- PsyMed Ventures
- Website
- https://psymed.ventures/
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PsyMed Ventures is a San Francisco-based venture capital fund investing exclusively in early-stage companies developing frontier brain and mental health technologies. The firm manages a 20+ company portfolio spanning neurotech, psychedelic therapeutics, RNA medicines, neurostimulation, digital health, and AI-assisted therapy, sourcing deals via founder networks and its Business Trip podcast.
- Ownership category
- akta.pro rank
PsyMed Ventures industry classification
Industry- Product category
- Venture Capital
- NAICS
- Other Investment Pools and Funds (5259), Other Financial Vehicles (52599)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- SDG / Thematic Sustainable Investment Funds (FSANAJAN)
Keywords
Where PsyMed Ventures is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
PsyMed Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Venture Capital Returns: Returns generated through equity investments in portfolio companies, realized through IPOs, acquisitions, and secondary transactions. VC funds typically charge 2% management fees on committed capital and 20% carry on profits.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
PsyMed Ventures product offering
Product offeringCore offering
PsyMed Ventures is a venture capital fund that makes equity investments in early-stage companies developing frontier brain and mental health technologies. The firm invests across neurotech, brain-computer interfaces, digital health, precision neuroscience, novel therapeutics, psychedelic medicine, and alternative modalities, while providing portfolio companies with strategic support, ecosystem connections, and operational guidance.
Product overview
PsyMed Ventures is a venture capital fund that invests in and supports founders developing brain and mental health innovations. Rather than operating a unified product platform, the firm provides investment and support to a portfolio of companies working across neurotech, digital health, precision neuroscience, and novel therapeutic modalities. The portfolio includes companies at various stages (active investments, IPO, acquired, and stealth) spanning RNAi medicines, CRISPR platforms, psychedelic therapeutics, VR/AR experiences, AI-assisted therapy tools, neurostimulation devices, and microbiome therapeutics.
Differentiator
Problem solved
Functional benefit
Products and services
- PsyMed Ventures Fund
- Angel Syndicate
Companies that use PsyMed Ventures
Customer profileSegments2 records
Ideal customer profiles2 records
PsyMed Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
PsyMed Ventures partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights4 records
PsyMed Ventures competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
PsyMed Ventures social profiles
Digital presencePsyMed Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
PsyMed Ventures leadership team
Management profileNumber of profiles
Profiles14 records
PsyMed Ventures funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PsyMed Ventures M&A and investment
M&A and investmentM&A
Investments25 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PsyMed Ventures
What does PsyMed Ventures do?
PsyMed Ventures is a venture capital fund that makes equity investments in early-stage companies developing frontier brain and mental health technologies. The firm invests across neurotech, brain-computer interfaces, digital health, precision neuroscience, novel therapeutics, psychedelic medicine, and alternative modalities, while providing portfolio companies with strategic support, ecosystem connections, and operational guidance.
Is PsyMed Ventures a public or private company?
PsyMed Ventures is a private company. It is classified as venture growth investor backed and is currently operating.
When was PsyMed Ventures founded?
PsyMed Ventures was founded in 2020. It employs 1 to 10 people.
Where is PsyMed Ventures based?
PsyMed Ventures is headquartered in San Francisco, United States, in the North America region.
How does PsyMed Ventures make money?
One revenue line is on record: venture Capital Returns.
Does PsyMed Ventures have an API?
No public API is recorded for PsyMed Ventures.
What industry is PsyMed Ventures in?
PsyMed Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAJAN, SDG / Thematic Sustainable Investment Funds. Its NAICS code is 5259 and its SIC code is 6282.